Welcome to the Boehringer Ingelheim Pharmaceuticals Inc.(BIPI) and Lilly USA, LLC (Lilly) Alliance on-line application and grant management portal.

      On January 11, 2011 BIPI and Lilly announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and measurably improves health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

      By agreement between BIPI and Lilly, grant requests will be processed through the BIPI on-line grant system but the application request will be reviewed by both companies. Please review the following prior to submitting a request through our on-line system.

      Medical Education Grants

      A BIPI/Lilly medical education grant is designed to support independent medical education for healthcare providers and patients that may translate to better management of disease and improvement in patient safety and population health.

      Please see below for submission timelines:

      • Grant applications must be submitted no less than 60 days prior to the program start date.

      New and Returning Visitors to BIPI/Lilly Medical Grants

      To begin a new application, return to a saved application, or track the status of an application already submitted login at https://bipisupport.envisionpharma.com/vt_bi/. If this is the first time you are visiting the site, you must register as a New User. An application ID beginning with "ME", will be assigned once you submit the application.

      Educational Objectives - Diabetes

      1. Improve clinicians’ understanding of the current guidelines and scientific evidence supporting individualized treatment and goals for Type 2 Diabetes and foster clinicians’ understanding of the barriers to care and how to address them, helping patients meet treatment goals.
      2. Enhance clinicians’ understanding of the benefit/risk profile of novel Type 2 diabetes therapies with supporting scientific and clinical evidence.
      3. Enhance clinicians' awareness and knowledge of the evidence-based treatment options to reduce macrovascular (stroke, myocardial infarction, heart failure) disease and nephropathy in Type 2 diabetes patients.
      4. To help improve the insulin experience, increase clinicians’ understanding of barriers faced by people with diabetes including the 1) insulin initiation experience 2) adherence and 3) persistence as well as the impact of these barriers on outcomes and appropriate strategies, including emotional support.

      Responding to a Request for Educational Grant Application (REGA)
      Throughout the year, the Medical Grants department may announce a Request for Educational Grant Application (REGA). The intent of this announcement is to notify experienced and accredited Continuing Medical Education (CME) providers and accredited Continuing Education (CE) providers that BIPI/Lilly is interested in receiving applications for educational grants for support consideration.

      Grant applications in response to BIPI/Lilly Alliance REGAs need to be submitted online at https://bipisupport.envisionpharma.com/vt_bi. While REGAs may specify timing of requested responses, BIPI and Lilly will continue to review all grant requests which are received.

      To contact the BIPI/Lilly Alliance Medical Grants Department, please send an email to medgrnts.rdg@boehringer-ingelheim.com.